Opinion|Videos|February 10, 2025
Navigating New Treatment Options for Pediatric Atopic Dermatitis Management
Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib), in the treatment of moderate to severe atopic dermatitis, emphasizing their effectiveness in improving outcomes for patients who do not have adequate control with conventional therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Where do you see the newer agents fitting into moderate to severe atopic dermatitis treatment?
- Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
- JAK inhibitors: abrocitinib, baricitinib, upadacitinib
Advertisement
Related to this article
Jon Matthew Farber, MD, shares his thoughts on the use of noninvasive brain stimulation for ADHD.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
A meta-analysis of 7 real-world studies found maternal RSVpreF 78% effective against RSV LRTI hospitalization in infants up to 6 months.
In 5.2 million US infants, newborn vitamin K nonreceipt rose to 6.8% by 2025 and was tied to a 47% higher bleeding risk by 6 months.
New real-world data reveal delays and disparities in nirsevimab administration, highlighting opportunities to improve timely RSV protection for infants.
Jessica Nash, MD, IBCLC, shares strategies for assessing breastfeeding, identifying latch problems, and connecting families with lactation resources.
Find out the 4 FDA decisions to watch in November 2026 for pediatric care.
Michael Pistiner, MD, discusses how pediatricians can support food allergy management in schools through accurate diagnosis, emergency plans, and education.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Skipping newborn vitamin K tied to 47% higher infant bleeding risk
2
Breastfeeding essentials: Assessing latch and milk transfer
3
Maternal RSVpreF 78% effective against infant RSV hospitalization
4
Study identifies gaps in infant RSV immunization timing
5